

**ICD-10-CM Casefinding List, 2025**  
**Based on the International Classification of Diseases, ICD-10-CM Tabular List of Diseases and Injuries, FY 2025**

For the full list of eligible individual ICD-10-CM codes, please refer to the [Excel Format](#).

| <b>COMPREHENSIVE ICD-10-CM Casefinding Code List for Reportable Tumors</b><br><b>(EFFECTIVE DATES: 10/1/2024-9/30/2025)</b> |  |
|---|--|
| <b>Please refer to your standard setter(s) for specific reporting requirements before using the Casefinding List</b>        |  |
| <b>ICD-10-CM Code</b>   | <b>Explanation of Code</b>   |
| C00- C43, C4A.-, C45- C96   | Malignant neoplasms (excluding C44), stated or presumed to be primary (of specified site) or secondary cancers and certain specified histologies   |
| C44.00, C44.09  | Unspecified/other malignant neoplasm of skin of lip  |
| C44.10_, C44.19_  | Unspecified/other malignant neoplasm of skin of eyelid   |
| C44.13-   | Sebaceous cell carcinoma of skin of eyelid, including canthus  |
| C44.20-, C44.29-  | Unspecified/other malignant neoplasm skin of ear and external auricular canal  |
| C44.30-, C44.39-  | Unspecified/other malignant neoplasm of skin of other/unspecified parts of face  |
| C44.40, C44.49  | Unspecified/other malignant neoplasm of skin of scalp & neck   |
| C44.50-, C44.59-  | Unspecified/other malignant neoplasm of skin of trunk  |
| C44.60-, C44.69-  | Unspecified/other malignant neoplasm of skin of upper limb, incl. shoulder   |
| C44.70-, C44.79-  | Unspecified/other malignant neoplasm of skin of lower limb, including hip  |
| C44.80, C44.89  | Unspecified/other malignant neoplasm of skin of overlapping sites of skin  |
| C44.90, C44.99  | Unspecified/other malignant neoplasm of skin of unspecified sites of skin  |
| D00.-- D05.-, D07.--  | In-situ neoplasms  |
| D09   | <p><i>Note 1: Excludes carcinoma in situ tumors of the cervix (D06._)</i></p> <p><i>Note 2: Excludes prostatic intraepithelial neoplasia (PIN III) (8148/2) of the prostate. Other prostate in situ histologies are reportable</i></p> <p><i>Note 3: For D04 (carcinoma in situ of skin), excludes basal and squamous cell in situ lesions</i></p>                             |
| D18.02  | Hemangioma of intracranial structures and any site   |
| D32.-   | Benign neoplasm of meninges (cerebral, spinal and unspecified)   |
| D33.-   | Benign neoplasm of brain and other parts of central nervous system   |
| D35.2 - D35.4   | Benign neoplasm of pituitary gland, craniopharyngeal duct and pineal gland   |
| D42.-, D43.-  | Neoplasm of uncertain or unknown behavior of meninges, brain, CNS  |
| D44.3 - D44.5   | Neoplasm of uncertain or unknown behavior of pituitary gland, craniopharyngeal duct and pineal gland   |
| D45   | <p>Polycythemia vera (9950/3)</p> <p>ICD-10-CM Coding instruction note: Excludes familial polycythemia (C75.0), secondary polycythemia (D75.1)</p>   |
| D46.-   | Myelodysplastic syndromes (9980, 9982, 9983, 9985, 9986, 9989, 9993)   |
| D47.02  | Systemic mastocytosis  |
| D47.1   | <p>Chronic myeloproliferative disease (9963/3, 9975/3)</p> <p>ICD-10-CM Coding instruction note: Excludes the following:</p> <p>Atypical chronic myeloid leukemia BCR/ABL-negative (C92.2_)</p> <p>Chronic myeloid leukemia BCR/ABL-positive (C92.1_)</p> <p>Myelofibrosis &amp; Secondary myelofibrosis (D75.81)</p> <p>Myelophthisic anemia &amp; Myelophthisis (D61.82)</p> |

**ICD-10-CM Casefinding List, 2025**  
**Based on the International Classification of Diseases, ICD-10-CM Tabular List of Diseases and Injuries, FY 2025**

**COMPREHENSIVE ICD-10-CM Casefinding Code List for Reportable Tumors**  
**(EFFECTIVE DATES: 10/1/2024-9/30/2025)**

**Please refer to your standard setter(s) for specific reporting requirements before using the Casefinding List**

| ICD-10-CM Code | Explanation of Code   |
|----------------|---|
| D47.3          | Essential (hemorrhagic) thrombocythemia (9962/3)<br>Includes: Essential thrombocytosis, idiopathic hemorrhagic thrombocythemia  |
| D47.4          | Osteomyelofibrosis (9961/3)<br>Includes: Chronic idiopathic myelofibrosis<br>Myelofibrosis (idiopathic) (with myeloid metaplasia)<br>Myelosclerosis (megakaryocytic) with myeloid metaplasia<br>Secondary myelofibrosis in myeloproliferative disease |
| D47.9          | Neoplasm of uncertain behavior of lymphoid, hematopoietic and related tissue, unspecified (9970/1, 9931/3)  |
| D47.Z-         | Neoplasm of uncertain behavior of lymphoid, hematopoietic and related tissue, unspecified (9960/3, 9970/1, 9971/3, 9931/3)<br><i>Note: Effective 1/1/2021, PTLD (9971/3) is no longer reportable (9971/1)</i>   |
| D49.6, D49.7   | Neoplasm of unspecified behavior of brain, endocrine glands and other CNS   |
| D72.11-        | Hypereosinophilic syndrome [HES] (9964/3)   |
| K31.A22        | Gastric intestinal metaplasia with high grade dysplasia   |
| N85.02         | Endometrial intraepithelial neoplasia [EIN]   |
| <b>R85.613</b> | <b>High grade squamous intraepithelial lesion on cytologic smear of anus (HGSIL)</b>  |
| R85.614        | Cytologic evidence of malignancy on smear of anus   |
| R87.614        | Cytologic evidence of malignancy on smear of cervix   |
| R87.623        | High grade squamous intraepithelial lesion on cytologic smear of vagina (HGSIL)   |
| R87.624        | Cytologic evidence of malignancy on smear of vagina   |
| R90.0          | Intracranial space-occupying lesion found on diagnostic imaging of central nervous system   |

**ICD-10-CM Casefinding List, 2025**  
**Based on the International Classification of Diseases, ICD-10-CM Tabular List of Diseases and Injuries, FY 2025**

**NOTE: Cases with the codes in the Supplemental list below should be screened as registry time allows. Experience in the SEER registries has shown that using the supplemental lists increases casefinding for benign brain and CNS, hematopoietic neoplasms, other reportable diseases and treatment related information**

| <b>SUPPLEMENTAL LIST (PART I) ICD-10-CM</b><br><b>(EFFECTIVE DATES: 10/1/2024-9/30/2025)</b>                         |   |
|--|---|
| <b>Please refer to your standard setter(s) for specific reporting requirements before using the Casefinding List</b> |   |
| <b>ICD-10-CM Code</b>  | <b>Explanation of Code</b>  |
| D06.-  | Carcinoma in situ of the cervix   |
| D13.7  | Benign neoplasm of endocrine pancreas<br><i>Note: Effective 1/1/2021: Review this code to look for the following which were previously a benign tumor of the pancreas, but is now malignant per ICD-O-3.2</i> <ul style="list-style-type: none"> <li>• Islet cell adenoma</li> <li>• Nesidioblastoma</li> <li>• Islet cell adenomatosis</li> <li>• Insulinoma</li> <li>• Beta cell adenoma</li> </ul>                                   |
| D21.4  | Benign neoplasm of connective and other soft tissue of abdomen<br><i>Note: Effective 1/1/2021: Review this code to look for the following which were previously a benign tumor of the pancreas, but is now malignant per ICD-O-3.2</i><br>Gastrointestinal stromal tumor, NOS/GIST, NOS/Gastrointestinal autonomic nerve tumor/GANT/Gastrointestinal pacemaker cell tumor (8936/1, now 8936/3)  |
| D23.9  | Other benign neoplasm of skin<br>Benign carcinoid tumors of other sites<br><i>Note: Effective 1/1/2021: Review these code to look for the following which were previously benign and borderline tumors, but are now malignant per ICD-O-3.2</i> <ul style="list-style-type: none"> <li>• Aggressive digital papillary adenoma (c44_) (8408/1, but now 8408/3)</li> </ul>  |
| D35.0-   | Benign neoplasm of adrenal gland<br><i>Note: Effective 1/1/2021: Review this code to look for the following which was previously a benign (8700/0) tumor of the adrenal gland, but is now malignant per ICD-O-3.2 (8700/3)</i> <ul style="list-style-type: none"> <li>• Pheochromocytoma</li> <li>• Adrenal medullary paraganglioma</li> <li>• Chromaffin paraganglioma</li> <li>• Chromaffin tumor</li> <li>• Chromaffinoma</li> </ul> |

**ICD-10-CM Casefinding List, 2025**  
**Based on the International Classification of Diseases, ICD-10-CM Tabular List of Diseases and Injuries, FY 2025**

**SUPPLEMENTAL LIST (PART I) ICD-10-CM**  
**(EFFECTIVE DATES: 10/1/2024-9/30/2025)**

| <b>Please refer to your standard setter(s) for specific reporting requirements before using the Casefinding List</b> |  |
|--|--|
| <b>ICD-10-CM Code</b>  | <b>Explanation of Code</b>   |
| D37.8  | <p>Neoplasm of uncertain behavior of other specified digestive organs (includes uncertain behavior of pancreas)</p> <p><i>Note: Effective 1/1/2021: Review this code to look for the following histologies which were previously borderline tumors, but are now malignant per ICD-O-3.2</i></p> <ul style="list-style-type: none"> <li>• Pancreatic endocrine tumor, NOS (C259, 8150/1, now 8150/3)</li> <li>• Islet cell tumor, NOS (C259, 8150/1, now 8150/3)</li> <li>• Glucagonoma, NOS (C259, 8152/1, now 8152/3)</li> <li>• Alpha cell tumor, NOS (C259, 8152/1, now 8152/3)</li> <li>• Glucagon-like peptid-producing tumor (C259, 8152/1, now 8152/3)</li> <li>• Somastostatinoma, NOS (8156/1, now 8156/3)</li> <li>• Somatostatin cell tumor, NOS (8156/1, now 8156/3)</li> <li>• Endocrine tumor, functioning, NOS (8158/1, now 8158/3)</li> </ul> <p>ACTH-producing tumor (8158/1, now 8158/3)</p> |
| D3A.-  | <p>Benign carcinoid tumors</p> <p><i>Note: Effective 1/1/2021: Review these codes to look for the following which were previously benign and borderline tumors, but are now malignant per ICD-O-3.2</i></p> <ul style="list-style-type: none"> <li>• Carcinoid tumor, argentaffinoma, NOS (8240/1, now 8241/3)</li> <li>• Enterochromaffin-like cell carcinoid, NOS (8242/1, now 8241/3)</li> </ul>  |
| D44.6  | <p>Neoplasm of uncertain behavior of carotid body</p> <p><i>Note: Effective 1/1/2021: Review this code to look for the following histologies which were previously borderline tumors, but are now malignant per ICD-O-3.2</i></p> <ul style="list-style-type: none"> <li>• Carotid body tumor/Carotid body paraganglioma (8692/1, now 8692/3)</li> </ul>   |
| D44.7  | <p>Neoplasm of uncertain behavior of aortic body and other paraganglia</p> <p><i>Note: Effective 1/1/2021: Review this code to look for the following histologies which were previously borderline tumors, but are now malignant per ICD-O-3.2</i></p> <ul style="list-style-type: none"> <li>• Paraganglioma, NOS (8680/1, now 8680/3)</li> <li>• Sympathetic paraganglioma (8681/1, now 8681/3)</li> <li>• Parasympathetic paraganglioma (8682/1, now 8682/3)</li> <li>• Glomulus jugulare tumor, NOS/jugular paraganglioma/juglotympanic paraganglioma (8690/1, now 8690/3)</li> <li>• Aortic body tumor/aortic body paraganglioma/aorticopulmonary paraganglioma (8691/1, now 8691/3)</li> <li>• Extra-adrenal paraganglioma, NOS/nonchromaffin paraganglioma, NOS/chemodectoma (8693/1, now 8693/3)</li> </ul>  |
| D48.0  | <p>Neoplasm of uncertain behavior of bone and articular cartilage</p> <p><i>Note: Effective 1/1/2021: Review this code to look for the following histologies which were previously borderline tumors, but are now malignant per ICD-O-3.2</i></p> <ul style="list-style-type: none"> <li>• Clear cell odontogenic tumor (9341/1, now 9341/3)</li> </ul>  |

**ICD-10-CM Casefinding List, 2025**  
**Based on the International Classification of Diseases, ICD-10-CM Tabular List of Diseases and Injuries, FY 2025**

**SUPPLEMENTAL LIST (PART I) ICD-10-CM**  
**(EFFECTIVE DATES: 10/1/2024-9/30/2025)**

| <b>Please refer to your standard setter(s) for specific reporting requirements before using the Casefinding List</b> |  |
|--|--|
| <b>ICD-10-CM Code</b>  | <b>Explanation of Code</b>   |
| D48.1  | <p>Neoplasm of uncertain behavior of connective and other soft tissue of abdomen</p> <p><i>Note: Effective 1/1/2021: Review this code to look for the following which were previously a benign tumor of the pancreas, but is now malignant per ICD-O-3.2</i></p> <p>Gastrointestinal stromal tumor, NOS/GIST, NOS/Gastrointestinal autonomic nerve tumor/GANT/Gastrointestinal pacemaker cell tumor (8936/1, now 8936/3)</p> |
| D49.2  | <p>Neoplasm of unspecified behavior of digestive organs (includes unspecified behavior of pancreas)</p> <p><i>Note: Review this code to look for the following which were previously unknown behavior tumors of the pancreas, but are now malignant tumors per ICD-O-3.2 (Histology 8150/3)</i></p> <ul style="list-style-type: none"> <li>• Pancreatic endocrine tumor, NOS</li> <li>• Islet cell tumor, NOS</li> </ul>     |
| D61.810  | Antineoplastic chemotherapy induced pancytopenia   |
| D64.81   | Anemia due to antineoplastic chemotherapy  |
| D70.1  | Agranulocytosis secondary to cancer chemotherapy   |
| D72.10   | Eosinophilia, NOS (Note: Screen for incorrectly coded Chronic eosinophilic leukemia, 9964/3)   |
| D75.81   | Myelofibrosis (note: this is not primary myelofibrosis [9961/3])   |
| E31.2-   | Multiple endocrine neoplasia [MEN] syndromes   |
| E34.0-   | Carcinoid syndrome   |
| E88.3  | Tumor lysis syndrome (following antineoplastic chemotherapy)   |
| G89.3  | Neoplasm related pain (acute)(chronic)   |
| H47.42   | Disorders of optic chiasm in (due to) neoplasm   |
| H47.52-  | Disorders of visual pathways in (due to) neoplasm  |
| H47.63-  | Disorders of visual cortex in (due to) neoplasm  |
| I31.31   | Malignant pericardial effusion in diseases classified elsewhere  |
| J70.0  | Acute pulmonary manifestations due to radiation  |
| J70.1  | Chronic and other pulmonary manifestations due to radiation  |
| J91.0  | Malignant pleural effusion   |
| K12.31   | Oral mucositis (ulcerative) due to antineoplastic therapy  |
| K12.33   | Oral mucositis (ulcerative) due to radiation   |
| K52.0  | Gastroenteritis and colitis due to radiation   |
| K62.7  | Radiation proctitis  |
| K62.82   | Dysplasia of anus (AIN I and AIN II)   |
| K92.81   | Gastrointestinal mucositis (ulcerated) (due to antineoplastic therapy)   |
| L58.-  | Radiodermatitis  |
| L59.8  | Other disorders of skin and subcutaneous tissue related to radiation   |
| L59.9  | Disorder of the skin and subcutaneous tissue related to radiation, unspecified   |
| M31.11   | Hematopoietic stem cell transplantation-associated thrombotic microangiopathy  |
| M96.2  | Postradiation kyphosis   |

**ICD-10-CM Casefinding List, 2025**  
**Based on the International Classification of Diseases, ICD-10-CM Tabular List of Diseases and Injuries, FY 2025**

**SUPPLEMENTAL LIST (PART I) ICD-10-CM**  
**(EFFECTIVE DATES: 10/1/2024-9/30/2025)**

**Please refer to your standard setter(s) for specific reporting requirements before using the Casefinding List**

| ICD-10-CM Code                  | Explanation of Code  |
|---------------------------------|--|
| M96.5                           | Postradiation scoliosis  |
| N30.4-                          | Irradiation cystitis   |
| N46.024                         | Azoospermia due to radiation   |
| N46.124                         | Oligospermia due to radiation  |
| N52.31-N52.32,<br>N52.34-N52.36 | Post procedural erectile dysfunction<br>(due to prostatectomy, cystectomy, radiation)  |
| O35.6-                          | Maternal care for (suspected) damage to fetus by radiation   |
| O9A.1-                          | Malignant neoplasm complicating pregnancy, childbirth and the puerperium   |
| P04.11                          | Newborn affected by maternal antineoplastic chemotherapy   |
| P04.12                          | Newborn affected by maternal cytotoxic drugs   |
| Q85.0-                          | Neurofibromatosis (nonmalignant) (9540/1)<br><i>Note: Neurofibromatosis is not cancer. These tumors can be precursors to acoustic neuromas, which are reportable</i>             |
| R18.0                           | Malignant ascites  |
| R53.0                           | Neoplastic (malignant) related fatigue   |
| R97.21                          | Rising PSA following treatment for malignant neoplasm of prostate  |
| T38.6-                          | Poisoning by antigenadotrophins, antiestrogens, antiandrogens, not elsewhere classified  |
| T38.8-, T38.9-                  | Poisoning by hormones and their synthetic substitutes  |
| T45.1-                          | Poisoning by, adverse effect of and under dosing of antineoplastic and immunosuppressive drugs   |
| T45.8-, T45.9-                  | Poisoning by primary systemic and hematological agent, unspecified   |
| T45.AX-                         | Poisoning by, adverse effect of and underdosing of immune checkpoint inhibitors and immunostimulant drugs  |
| T66.-                           | Unspecified effects of radiation   |
| T80.81-                         | Extravasation of vesicant agent  |
| T80.82-                         | Complication of immune effector cellular therapy<br>- Complication of chimeric antigen receptor (CAR-T) cell therapy   |
| T86.0-                          | Complications of bone marrow transplant  |
| Y63.2                           | Overdose of radiation given during therapy   |
| Y84.2                           | Radiological procedure and radiotherapy as the cause of abnormal reaction of the patient, or of later complication, without mention of misadventure at the time of the procedure |
| Z08                             | Encounter for follow-up examination after completed treatment for malignant neoplasm (medical surveillance following completed treatment)  |
| Z40.0-                          | Encounter for prophylactic surgery for risk factors related to malignant neoplasms   |
| Z42.1                           | Encounter for breast reconstruction following mastectomy   |
| Z48.290                         | Encounter for aftercare following bone marrow transplant   |
| Z48.3                           | Aftercare following surgery for neoplasm   |
| Z51.0                           | Encounter for antineoplastic radiation therapy   |

***ICD-10-CM Casefinding List, 2025***  
***Based on the International Classification of Diseases, ICD-10-CM Tabular List of Diseases and Injuries, FY 2025***

**SUPPLEMENTAL LIST (PART I) ICD-10-CM**  
**(EFFECTIVE DATES: 10/1/2024-9/30/2025)**

**Please refer to your standard setter(s) for specific reporting requirements before using the Casefinding List**

| ICD-10-CM Code                   | Explanation of Code   |
|----------------------------------|---|
| Z51.1-                           | Encounter for antineoplastic chemotherapy and immunotherapy   |
| Z51.5, Z51.89                    | Encounter for palliative care and other specified aftercare   |
| Z79.63-                          | Long term (current) use of chemotherapeutic agent   |
| Z79.64                           | Long term (current) use of myelosuppressive agent (hydroxyurea)   |
| Z79.81-                          | Long term (current) use of agents affecting estrogen receptors and estrogen levels                                      |
| Z85.-                            | Personal history of malignant neoplasm  |
| Z86.00-                          | Personal history of in situ neoplasm  |
| Z86.010                          | Personal history of colonic polyps  |
| Z86.011                          | Personal history of benign neoplasm of the brain  |
| Z86.012                          | Personal history of benign carcinoid tumor  |
| Z92.21, Z92.23,<br>Z92.25, Z92.3 | Personal history of antineoplastic chemotherapy, estrogen therapy, immunosuppression therapy or irradiation (radiation) |
| Z92.26                           | Personal history of immune checkpoint inhibitor (ICI) (drug) therapy  |
| Z92.850                          | Personal history of Chimeric Antigen Receptor T-cell therapy<br>- Personal history of CAR-T-cell therapy                |
| Z94.81, Z94.84                   | Bone marrow and stem cell transplant status   |